Decision Resources, one of the world's leading preliminaries and consultatory firms for sedative and healthcare issues, finds that the recent decision by the U.S. Food and Drug superintendence (FDA) to grant sanctionative




if (lexico_globals.googleafc.ads.content.length)
{
document.write(lexico_globals.googleafc.ads.contenttop);
document.write(lexico_globals.googleafc.ads.sponsoredlinks);
document.write(lexico_globals.googleafc.ads.content[2]);
document.wr of AstraZeneca's Seroquel XR for adjunctive care of major bipolar affective ailment illness will not change Decision Resources' market forecast for the indication. As antecedently forecasted, Seroquel and Seroquel XR will garner nearly one quarter of antipsychotics sales as adjunctive treatments for major manic-depressive psychosis trouble in 2013 in the world's major stimulant markets.

More: - From the site